Urologic cancers in Korea

Kyo Chul Koo, Kwang Suk Lee, Byung Ha Chung

Research output: Contribution to journalShort survey

8 Citations (Scopus)

Abstract

The incidence and prevalence of prostate and kidney cancers have been increasing in Korea during the last decade, and a marked improvement in survival rates has been noted. With a substantial proportion of the cancers diagnosed at an earlier stage of the disease, the landscape of urologic cancer treatment in Korea has been characterized by an exponential increase in the number of patients receiving surgical treatment. Throughout the last decade, an increasing proportion of surgeries have been performed using minimally invasive methods, with a notable increase in robot-assisted surgery. The evaluation and management strategies of urologic cancer in Korea are primarily based on an existing evidence-based framework provided by international guidelines. The adoption and clinical application of novel surgical techniques and systemic agents targeted at advanced stage cancer are promptly adopted; accordingly, multidisciplinary treatment options are often available for various cancers at different stages. At the same time, treatment decisions are greatly influenced by the availability of healthcare resources, which may be limited due to the National Health Insurance reimbursement policy. A racial disparity in cancer features appears to exist for certain urologic cancers among Korean patients, and the optimal management strategy specific for the Korean population has yet to be confirmed. A national comprehensive cancer database is needed for better insight into risk factors, selection of sequential strategies, tumor biology and survival outcome of Korean urologic cancer patients.

Original languageEnglish
Article numberhyv096
Pages (from-to)805-811
Number of pages7
JournalJapanese Journal of Clinical Oncology
Volume45
Issue number9
DOIs
Publication statusPublished - 2015 Sep 1

Fingerprint

Urologic Neoplasms
Korea
Neoplasms
Health Insurance Reimbursement
Kidney Neoplasms
National Health Programs
Therapeutics
Prostatic Neoplasms
Survival Rate
Databases
Guidelines
Delivery of Health Care
Survival
Incidence
Population

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Koo, Kyo Chul ; Lee, Kwang Suk ; Chung, Byung Ha. / Urologic cancers in Korea. In: Japanese Journal of Clinical Oncology. 2015 ; Vol. 45, No. 9. pp. 805-811.
@article{a6056e7a2fb44269adb7df19065efc9e,
title = "Urologic cancers in Korea",
abstract = "The incidence and prevalence of prostate and kidney cancers have been increasing in Korea during the last decade, and a marked improvement in survival rates has been noted. With a substantial proportion of the cancers diagnosed at an earlier stage of the disease, the landscape of urologic cancer treatment in Korea has been characterized by an exponential increase in the number of patients receiving surgical treatment. Throughout the last decade, an increasing proportion of surgeries have been performed using minimally invasive methods, with a notable increase in robot-assisted surgery. The evaluation and management strategies of urologic cancer in Korea are primarily based on an existing evidence-based framework provided by international guidelines. The adoption and clinical application of novel surgical techniques and systemic agents targeted at advanced stage cancer are promptly adopted; accordingly, multidisciplinary treatment options are often available for various cancers at different stages. At the same time, treatment decisions are greatly influenced by the availability of healthcare resources, which may be limited due to the National Health Insurance reimbursement policy. A racial disparity in cancer features appears to exist for certain urologic cancers among Korean patients, and the optimal management strategy specific for the Korean population has yet to be confirmed. A national comprehensive cancer database is needed for better insight into risk factors, selection of sequential strategies, tumor biology and survival outcome of Korean urologic cancer patients.",
author = "Koo, {Kyo Chul} and Lee, {Kwang Suk} and Chung, {Byung Ha}",
year = "2015",
month = "9",
day = "1",
doi = "10.1093/jjco/hyv096",
language = "English",
volume = "45",
pages = "805--811",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "9",

}

Urologic cancers in Korea. / Koo, Kyo Chul; Lee, Kwang Suk; Chung, Byung Ha.

In: Japanese Journal of Clinical Oncology, Vol. 45, No. 9, hyv096, 01.09.2015, p. 805-811.

Research output: Contribution to journalShort survey

TY - JOUR

T1 - Urologic cancers in Korea

AU - Koo, Kyo Chul

AU - Lee, Kwang Suk

AU - Chung, Byung Ha

PY - 2015/9/1

Y1 - 2015/9/1

N2 - The incidence and prevalence of prostate and kidney cancers have been increasing in Korea during the last decade, and a marked improvement in survival rates has been noted. With a substantial proportion of the cancers diagnosed at an earlier stage of the disease, the landscape of urologic cancer treatment in Korea has been characterized by an exponential increase in the number of patients receiving surgical treatment. Throughout the last decade, an increasing proportion of surgeries have been performed using minimally invasive methods, with a notable increase in robot-assisted surgery. The evaluation and management strategies of urologic cancer in Korea are primarily based on an existing evidence-based framework provided by international guidelines. The adoption and clinical application of novel surgical techniques and systemic agents targeted at advanced stage cancer are promptly adopted; accordingly, multidisciplinary treatment options are often available for various cancers at different stages. At the same time, treatment decisions are greatly influenced by the availability of healthcare resources, which may be limited due to the National Health Insurance reimbursement policy. A racial disparity in cancer features appears to exist for certain urologic cancers among Korean patients, and the optimal management strategy specific for the Korean population has yet to be confirmed. A national comprehensive cancer database is needed for better insight into risk factors, selection of sequential strategies, tumor biology and survival outcome of Korean urologic cancer patients.

AB - The incidence and prevalence of prostate and kidney cancers have been increasing in Korea during the last decade, and a marked improvement in survival rates has been noted. With a substantial proportion of the cancers diagnosed at an earlier stage of the disease, the landscape of urologic cancer treatment in Korea has been characterized by an exponential increase in the number of patients receiving surgical treatment. Throughout the last decade, an increasing proportion of surgeries have been performed using minimally invasive methods, with a notable increase in robot-assisted surgery. The evaluation and management strategies of urologic cancer in Korea are primarily based on an existing evidence-based framework provided by international guidelines. The adoption and clinical application of novel surgical techniques and systemic agents targeted at advanced stage cancer are promptly adopted; accordingly, multidisciplinary treatment options are often available for various cancers at different stages. At the same time, treatment decisions are greatly influenced by the availability of healthcare resources, which may be limited due to the National Health Insurance reimbursement policy. A racial disparity in cancer features appears to exist for certain urologic cancers among Korean patients, and the optimal management strategy specific for the Korean population has yet to be confirmed. A national comprehensive cancer database is needed for better insight into risk factors, selection of sequential strategies, tumor biology and survival outcome of Korean urologic cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=84942307167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942307167&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyv096

DO - 10.1093/jjco/hyv096

M3 - Short survey

C2 - 26117494

AN - SCOPUS:84942307167

VL - 45

SP - 805

EP - 811

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 9

M1 - hyv096

ER -